Overview
Bempedoic acid pregnancy surveillance program
Description
A surveillance study of females exposed to bempedoic acid or bempedoic acid/ezetimibe fixed combination drug product (FCDP) during pregnancy. Observational outcome data will be collected on pregnant females through pregnancy and infants through the first year of life.
Eligibility
Inclusion Criteria:
Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time
during pregnancy (from first day of last menstrual period [LMP] to pregnancy outcome
Exclusion Criteria: